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W
e read with great interest and appreciation
the article by Meagher et al. (1). Here, treat-
ment of NOD mice with anti–interleukin-16
(IL-16) antibodies results in type 1 diabetes
prevention by interfering with CD4
1 T-cell recruitment to
the pancreas. IL-16 is a chemoattractant factor for CD4
1 T
cells that is released in its bioactive form by caspase-3
cleavage of pro–IL-16. In the current study, IL-16 is
reported to be produced within the insulitic lesion by B220
B cells and CD4
1/CD8
1 T cells, rather than by the pan-
creatic islets. However, immunoﬂuorescence studies with
colocalization for IL-16 and active caspase-3 in islet-
inﬁltrating cells show that although many lymphocytes
constitutively express pro–IL-16, only a few stain for acti-
vated caspase-3 resulting in low levels of mature IL-16.
We have previously shown that patients who have type 1
diabetes or are affected by endocrinopathies such as au-
toimmune polyendocrine syndrome type 2 and autoim-
mune thyroiditis present a reduced expression of active
caspase-3 in peripheral T cells (2,3). Similar ﬁndings have
also been recently extended to the peripheral T cells of
patients with multiple sclerosis (4). Importantly, in NOD
mice treated with cyclophosphamide to accelerate di-
abetes development, active caspase-3 expression within
the islets is rarely observed in CD4
1 and CD8
1 T cells (5).
Overall, we believe that these studies can explain the
low levels of mature IL-16 detected in the inﬂamed islets.
Although signal ampliﬁcation with tyramide, similar to IL-16
stainings, could have improved the detection of active
caspase-3, in our opinion a reduced expression of active
caspase-3 in inﬁltrating T cells could account for the low
levels of IL-16 detected in the insulitic lesion. The obser-
vation that the treatment of NOD mice with anti–IL-16
results in an increased apoptosis of CD4
1 T cells is not
detrimental to this hypothesis because the exact mecha-
nism underlying this process is unknown. In the NOD
mouse, T cells may then be partially defective in IL-16
secretion, but still capable of releasing enough IL-16 for
the recruitment of CD4
1 T cells and diabetes development.
ACKNOWLEDGMENTS
No potential conﬂicts of interest relevant to this article
were reported.
REFERENCES
1. Meagher C, Beilke J, Arreaza G, et al. Neutralization of interleukin-16 pro-
tects nonobese diabetic mice from autoimmune type 1 diabetes by a CCL4-
dependent mechanism. Diabetes 2010;59:2862–2871
2. Vendrame F, Santangelo C, Misasi R, et al. Defective lymphocyte caspase-3
expression in type 1 diabetes mellitus. Eur J Endocrinol 2005;152:119–125
3. Vendrame F, Segni M, Grassetti D, et al. Impaired caspase-3 expression by
peripheral T cells in chronic autoimmune thyroiditis and in autoimmune
polyendocrine syndrome-2. J Clin Endocrinol Metab 2006;91:5064–5068
4. Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in
patients with multiple sclerosis, following therapeutic lymphocyte depletion
with alemtuzumab (Campath-
1H). J Clin Invest 2009;119:2052–2061
5. Reddy S, Bradley J, Ginn S, Pathipati P, Ross JM. Immunohistochemical
study of caspase-3-expressing cells within the pancreas of non-obese di-
abetic mice during cyclophosphamide-accelerated diabetes. Histochem Cell
Biol 2003;119:451–461
From the
1Diabetes Research Institute, University of Miami, Miami, Florida;
the
2Fondazione Umberto Di Mario Organizzazione Non Lucrativa di Utilita’
Sociale, Toscana Life Science Park, Siena, Italy; and the
3Diabetes Unit,
Department of Internal Medicine, Endocrine and Metabolic Sciences and
Biochemistry, University of Siena, Siena, Italy.
Corresponding author: Francesco Vendrame, fvendrame@med.miami.edu.
DOI: 10.2337/db10-1489
 2011 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
e12 DIABETES, VOL. 60, FEBRUARY 2011 diabetes.diabetesjournals.org
ONLINE LETTERS TO THE EDITOR